About Mitralign

Mitralign Inc.MITRALIGN, INC.

Mitralign, Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. We are a venture-backed, medical innovation company located near Boston, Massachusetts, USA.

We’ve developed an innovative therapy for the reduction of functional mitral regurgitation (FMR), a life-threatening cardiac condition affecting four million people in the U.S. alone1. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation (MR ≥ 3+) for annular reduction through tissue plication. In addition, we have developed an approach to treating tricuspid valve regurgitation with a delivery system designed for transcatheter tricuspid valve repair. Our unique system provides a new solution for interventional cardiologists and their patients.

For the millions of patients who’ve exhausted other therapeutic options, Mitralign is a lifeline.

  1. Jamieson WR, Edwards FH, Schwartz M, et al. Risk Stratification for Cardiac Valve Replacement. National Cardiac Surgery Database. Database Committee of the Society of Thoracic Surgeons. Ann Thorac Surg 1999;67:943-951

Management team

Board of Directors

Back to top

Mr. Geoffrion currently serves as the President and Chief Executive Officer of Mitralign, a venture-backed private company that has developed a transcatheter platform for mitral and tricuspid valve repair. Rick has over 30 years of management experience in the medical device industry and more than 25 years in the cardiovascular device space. A co-founder of Mitralign, he previously led the company foundation and served as the early stage CEO for three additional medical device companies (CircuLite, FlowMedica, X-Cell). He also guided the recapitalization and redirection of two successful medical device companies (Impella, Pathway). Mr. Geoffrion served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc. He holds a BSME and an MBA from the University of Connecticut.

Lisa Wipperman Heine brings over 25 years of medical device experience to Mitralign. Prior to joining Mitralign, she was the Founder and Principal at deArca Strategic Solutions, LLC, a consulting firm focused on helping medtech companies assess, develop and execute strategies related to market opportunities and technology adoption.  Lisa has also served in multiple leadership roles at Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business unit and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement and Medical Education functions. Lisa also currently serves as a member of the Board of Directors of both Surmodics Inc. (NASDAQ: SRDX) and Natus Medical Inc. (NASDAQ: BABY).  She received her undergraduate degree from St. Olaf College and graduate degree from the University of Manitoba.

Dr. Groothuis brings a wealth of experience to Mitralign. Prior to joining Mitralign, he was the VP and COO at CBSET, where he was responsible for research in cardiovascular devices. Previously, he was Assoc. Director of the Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He was also a Research Associate in the Harvard-MIT. Division of Health Sciences and Technology. Dr. Groothuis has authored numerous journal articles in the area of cardiovascular diseases. He received his BS from the University of California, Irvine, MS from Georgetown University, MBA from Salem State University and his PhD from Southern New Hampshire University.

Mr. Schleifer has over 20 years experience in the medical device, biotech and pharmaceutical industry. Prior to joining Mitralign, he held several key positions in management for Boston Scientific Corporation. During his eight-year tenure at BSC, he was responsible for business planning, product positioning and messaging, integrated channel management, competitive strategies and KOL management. Mr. Schleifer also has experience managing and monitoring Phase II-IV clinical trials for major pharmaceutical products and medical devices. Mr. Schleifer received his BA in Psychology from Kenyon College and holds an MBA from Babson College.

Lisa Mastromattei has over 25 years of experience in Finance & Accounting, primarily in the medical device industry.  Prior to joining Mitralign, Lisa held several leadership roles including Director of Accounting at Orchard Brands, a direct marketing/ecommerce business.  Global Controller at Microline Surgical, a manufacturer of high precision laparoscopic instruments.  Lisa also spent 15 years at Abbott Laboratories, Diabetes Care division.  She received her bachelor’s degree cum laude from Suffolk University in Finance and holds a Six Sigma Black Belt.

Mr. Oppenheim brings 20 years of diverse operations experience serving medical, defense, scientific, industrial, and automotive markets.  In addition to operations, he has held strategic roles in product management and business integration.  Mr. Oppenheim received his BS from the University of Great Falls, an MBA from the University of Massachusetts Lowell, and is a Certified Six Sigma Blackbelt.

Mr. Lee has over 20 years of experience in development and manufacturing of medical devices. Prior to joining Mitralign, he was with LightLab Imaging, now part of St. Jude Medical, Inc. Mr. Lee has held product development leadership roles at Surgivision, GMP Companies, C.R. Bard, Inc./AVE and Medtronic. He has a BS cum laude in Mechanical Engineering from Northeastern University.

Sara Vidmar has over 20 years of medical device experience with a focus on cardiovascular products and procedures. Prior to joining Mitralign, Sara held several roles at Medtronic including leading the clinical organizations for the Structural Heart and Cardiac Rhythm Heart Failure Management as well as a corporate clinical leadership role focused on addressing the need for real-world, longitudinal product performance and patient safety data. Sara’s other prior roles included Vice President, Clinical Research and Scientific Affairs at Lutonix-CR Bard where she was responsible for achieving FDA and global regulatory approvals for the drug-coated balloon therapy. Sara received her bachelor’s degree from University of Colorado, Boulder in Molecular, Cellular, Developmental Biology and her MBA from University of St. Thomas in Healthcare Management.

Mr. Geoffrion currently serves as the President and Chief Executive Officer of Mitralign, a venture-backed private company that has developed a transcatheter platform for mitral and tricuspid valve repair. Rick has over 30 years of management experience in the medical device industry and more than 25 years in the cardiovascular device space. A co-founder of Mitralign, he previously led the company foundation and served as the early stage CEO for three additional medical device companies (CircuLite, FlowMedica, X-Cell). He also guided the recapitalization and redirection of two successful medical device companies (Impella, Pathway). Mr. Geoffrion served as the Chairman of Impella CardioSystems AG, CircuLite and FlowMedica, Inc. He holds a BSME and an MBA from the University of Connecticut.

Ms. Bates is managing partner of Triathlon Medical Ventures. She has over 20 years of venture and operating experience, with a focus on medical devices and pharmaceuticals. At Guidant Corp., she ran Compass, its ventures group. Prior to that, she held various senior management operating positions at Eli Lilly. She is Chairman of the Board of CS-Keys, Inc. and on the Board of Directors at Pradama. She was also on the Board of Directors at Remon Medical Technologies before its acquisition of Boston Scientific. Ms. Bates has an MBA from Stanford, a BS in Finance and a BS in Computer Science; she is also a CPA.

Dr. Yuval Binur is a co-founder of Mitralign and has been a board member since inception. He has over 30 years of worldwide venture capital and investment experience. In 2000, He had co-founded Accelerated Technologies, Inc., a differentiated investment firm focused on medical technologies. Prior to that, Dr. Binur has been a founding partner of Medica Ventures, an Israeli based global life sciences and medical technologies investment fund. Throughout the 80s, Dr. Binur was a member of Adler & Co., a leading, diversified New York based venture capital firm. Dr. Binur has been a board member of over 40 venture-backed companies in medical devices, pharmaceuticals and other technologies. Among them: PVT (now Edwards Lifesciences’ Sapien), superDimension (now owned by Covidien), Impella (now owned by Abiomed), Memory Pharmaceuticals (now owned by Roche), Pathway Medical (now owned by Bayer), Oxigene Pharmaceuticals (now owned by Roche) and Zoran Inc, a silicon company (now publicly traded). During his career in venture capital, Dr. Binur has been involved with major M&A transactions totaling over USD 3 billion. Dr. Binur has been involved with innovative medical, imaging, silicon, automotive and defense companies originated in Israel and in the US. During the last 8 years, Dr. Binur is active in the emerging markets and their medical needs with a main focus on China.  Dr. Binur main interest is in cardiovascular diseases. He is a member of the organizing committees of ICI (Israel), CCI (China) and CSI (Europe) conferences.

Aditya Puri is an Investment Partner at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, the Malaysian government’s strategic investment fund.  He joined Khazanah Nasional’s Life Sciences team after moving from the greater Boston area where he was working with Healthcare and Cleantech startups affiliated with Harvard and MIT.  He has more than 20 years of experience and leadership encompassing general management, private equity and venture investments, and international expansion across life science and technology industries.  His prior experience includes P&L responsibility and leadership positions at Yankee Group, a global technology research and consulting company, and Corporate Development at Boston Scientific, a Fortune 500 medical device manufacturer.  He serves on boards of multiple public and private life sciences companies in the US, and private companies outside the US.  He received his B.S. from the University of Southern Maine, graduating Summa Cum Laude, and his MBA from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.

Mr. Van Osch was a founding partner of Forbion Capital Partners. He currently serves on the Board of Directors for CircuLite, PneumRx and Santaris Pharma AS. Mr. Van Osch’s experience in the life sciences industry also includes positions at Cambridge Drug Discovery Ltd, Impella Cardiosystems, Acadia Pharmaceuticals and Flowmedica. While at ABN AMRO Capital, he developed the Medical Device investment strategy by joining the ATI incubator initiative which focused on start-ups in interventional cardiology.

Dr. HE is Director for Business Development and Licensing at Beijing Tide Pharmaceutical Co. Ltd., Beijing Tide is a major subsidiary of Sinobiopharm – a leading healthcare listing company in Hong Kong with market cap over USD 20 billion. Prior to that, He worked in Bank of China (Hong Kong) and was responsible for corporate finance in healthcare sector.  Dr. He holds a BS in biomedical engineering from Hong Kong Polytecnic  University and PhD in orthopaedics and traumatology from The Chinese University of Hong Kong. He is also a Chartered Financial Analyst (CFA).

Please indicate your site location

Mitralign, Inc.

This site may contain information on worldwide products, not all of which are available in every location. A reference to a product on this site does not imply that such product is or will be available in your location. The products referred to on this site may be subject to different regulatory requirements depending on the country of use. Consequently, visitors may be notified that certain sections of this site are intended only for health care professionals in certain countries. For the availability of a particular product in your country, please contact the company directly.